MedTrace Logo

Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis

NCT01148264 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-05-11

No results posted yet for this study

Summary

This trial is designed to evaluate olanzapine compared to the metoclopramide in the treatment of break through emesis after prophylaxis with dexamethasone, 5-HT 3 receptor antagonists and aprepitant in patients receiving chemotherapy. Efficacy will be assessed using a modified MASCC questionaire with a visual analog scale.

Conditions

  • Emesis

Interventions

DRUG

olanzapine

1x10mg per day for three days

DRUG

metoclopramide

3x10mg per day for three days

Sponsors & Collaborators

  • Karin Jordan

    lead OTHER

Principal Investigators

  • Karin Jordan, MD · Martin-Luther-University Halle-Wittenberg

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2013-10-31
Completion
2014-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01148264 on ClinicalTrials.gov